According to a recent LinkedIn post from MintNeuro, the U.K.’s Advanced Research + Invention Agency has launched a £50 million funding call for a Massive Scalable Neurotechnologies programme. The initiative is described as targeting neurotechnologies that access the central nervous system via natural pathways and can be deployed in under 30 minutes.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post highlights that ARIA’s goal of responsive neural interfaces with lower procedural burden aligns with MintNeuro’s focus on smaller, less invasive neurotechnology. MintNeuro links this direction to the role of integrated circuits in enabling miniaturization and adoption across devices such as smartphones, hearing aids, pacemakers, and wearables.
The company’s LinkedIn commentary suggests it is positioning itself as a potential collaborator for bidders focused on silicon, packaging, integration, and evaluation hardware. For investors, this may indicate an intention to align with publicly funded U.K. neurotech initiatives, which could expand MintNeuro’s partnership pipeline and validate its technology roadmap.
The post also lists key ARIA programme dates, with applications opening on February 24, 2026, a webinar on March 2, 2026, and a concept paper deadline of March 17, 2026. While no specific projects or contracts are mentioned for MintNeuro, early engagement with this funding call could place the company within a network of grant-backed neurotechnology developers and potentially enhance its visibility in the medtech and brain–computer interface ecosystem.